Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway

[1] Vincent A(2001)Myasthenia gravis Lancet 357 2122-8

[2] Palace J(2000)Helper T cells in antibody-mediated, organ-specific autoimmunity Curr Opin Immunol 12 664-9

[3] Hilton-Jones D(2004)Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats J Immunol 172 2697-703

[4] Elson CJ(2013)New treatments for myasthenia: a focus on antisense oligonucleotides Drug Des Devel Ther 7 13-7

[5] Barker RN(2008)Etanercept treatment in myasthenia gravis Ann N Y Acad Sci 1132 300-4

[6] Baggi F(2011)Treatment of myasthenia gravis based on its immunopathogenesis J Clin Neurol 7 173-83

[7] Annoni A(2003)Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells Cell Immunol 223 63-9

[8] Ubiali F(2004)Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells Neurobiol Dis 16 461-7

[9] Milani M(2005)Long-term effects of IFN-gamma, IL-10, and TGF-beta-modulated dendritic cells on immune response in Lewis rats J Clin Immunol 25 50-6

[10] Longhi R(2010)Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dendritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile Inflamm Res 59 197-205

[1] Vincent A(2001)Myasthenia gravis Lancet 357 2122-8

[2] Palace J(2000)Helper T cells in antibody-mediated, organ-specific autoimmunity Curr Opin Immunol 12 664-9

[3] Hilton-Jones D(2004)Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats J Immunol 172 2697-703

[4] Elson CJ(2013)New treatments for myasthenia: a focus on antisense oligonucleotides Drug Des Devel Ther 7 13-7

[5] Barker RN(2008)Etanercept treatment in myasthenia gravis Ann N Y Acad Sci 1132 300-4

[6] Baggi F(2011)Treatment of myasthenia gravis based on its immunopathogenesis J Clin Neurol 7 173-83

[7] Annoni A(2003)Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells Cell Immunol 223 63-9

[8] Ubiali F(2004)Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells Neurobiol Dis 16 461-7

[9] Milani M(2005)Long-term effects of IFN-gamma, IL-10, and TGF-beta-modulated dendritic cells on immune response in Lewis rats J Clin Immunol 25 50-6

[10] Longhi R(2010)Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dendritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile Inflamm Res 59 197-205